臨床基因組學市場：按產品/服務、技術、應用、感染疾病、最終用戶和地區分類

臨床基因組學市場規模預計在 2025 年達到 125 億美元，預計在 2032 年達到 263 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 11.2%。

全球臨床基因組學市場是醫療保健產業中一個快速發展的領域，它從根本上改變了個人化醫療和精準治療的模式。臨床基因組學涵蓋對個別基因組成的全面分析，為醫療決策、疾病診斷、治療選擇和預後提供資訊。這個多學科領域彌合了基因組學研究與臨床實踐之間的差距，使醫療保健提供者能夠根據患者獨特的基因特徵提供量身定做的醫療干預措施。

該市場涵蓋廣泛的技術、服務和應用，包括全基因組定序、標靶基因組合、藥物基因組學檢測、腫瘤基因組學和罕見疾病診斷。隨著全球醫療保健系統日益採用精準醫療方法，臨床基因組學已成為推動藥物開發、生物標記發現和治療最佳化創新的基礎技術。先進定序技術、人工智慧和巨量資料分析的整合顯著提高了基因組檢測的可及性、準確性和成本效益，使其更易於在全球不同的醫療機構和患者群體中常規臨床實施。

市場動態

全球臨床基因組學市場受到多種強勁促進因素的推動，這些因素持續加速其成長軌跡。遺傳性疾病、癌症和罕見疾病的全球流行催生了對精準診斷和治療解決方案的巨大需求，使得臨床基因組學成為醫療保健提供者的重要工具。次世代定序(NGS) 技術的進步、基因組檢測成本的下降以及數據解讀能力的提升，使得基因組分析更加便捷實用，並最終被廣泛應用於臨床。政府的舉措以及對基因組研究的大量投資，例如國家基因組計劃和精準醫療項目，正在為市場擴張提供強勁動力。

醫療專業人員和患者對個人化醫療益處的認知不斷提高，再加上全球醫療支出的不斷增加，進一步推動了市場成長。然而，市場面臨重大阻礙，包括不同地區法律規範複雜且各不相同，對市場參與企業構成了合規挑戰。高昂的初始基礎設施成本、熟練的基因組學專業人員短缺以及對資料隱私和安全的擔憂對發展構成了重大障礙，尤其是在新興經濟體中。圍繞基因檢測的倫理考量和潛在的歧視問題也限制了市場應用。由於藥物基因組學的應用不斷擴大，可以最佳化藥物選擇和給藥策略，以及人工智慧和機器學習機會的日益融合，以增強數據分析和解釋，因此存在巨大的商機。雖然新興市場提供了尚未開發的成長潛力，照護現場基因組檢測和液態切片技術的持續創新為市場擴張和改善患者預後提供了有希望的途徑。

本次調查的主要特點

• 本報告對全球臨床基因組學市場進行了詳細分析，並提供了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），以 2024 年為基準年。
• 它強調了各個領域的潛在商機，並描述了該市場的一系列有吸引力的投資提案。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
• 它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球臨床基因組學市場的主要企業。
• 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、最新策略、市場擴張和行銷策略做出明智的決策。
• 全球臨床基因組學市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過分析全球臨床基因組學市場所使用的各種策略矩陣來促進決策。

目錄

第1章：調查目標和先決條件

• 調查目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、法規與趨勢分析

• 市場動態
• 驅動程式
• 抑制因素
• 機會
• 影響分析
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景
• 產業趨勢

4. 2020 年至 2032 年全球臨床基因體學市場（按產品和服務分類）

• 介紹
• 設備或系統
• 序列器
• 耗材
• 試劑和套件
• 軟體和服務
• 數據分析與解釋

5. 全球臨床基因體學市場（依技術分類），2020 年至 2032 年

• 介紹
• 下一代定序（NGS）
• 聚合酵素鏈鎖反應（PCR）
• 微陣列
• 桑格定序
• 其他技術（例如 FISH、核型分析）

6. 全球臨床基因體學市場（按應用），2020 年至 2032 年

• 介紹
• 腫瘤學
• 癌症診斷和預後
• 感染疾病
• 病原體鑑定和表徵（細菌、病毒、真菌、寄生蟲）
• 遺傳性疾病
• 新生兒篩檢
• 心血管疾病
• 遺傳性心肌病檢測
• 神經系統疾病
• 神經退化性疾病檢測（例如阿茲海默症、亨丁頓舞蹈症）
• 其他應用（例如藥物基因體學）

7. 2020 年至 2032 年全球臨床基因體學市場（依最終使用者分類）

• 介紹
• 醫院和診所
• 診斷實驗室
• 製藥和生物技術公司
• 其他（學術研究機構等）

8. 全球臨床基因體學市場（按地區分類），2020 年至 2032 年

• 介紹
• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 東南亞國協
  • 其他亞太地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
• 非洲
  • 南非
  • 北非
  • 中部非洲

第9章 競爭態勢

• Illumina Inc
• Thermo Fisher Scientific Inc
• F Hoffmann-La Roche Ltd
• QIAGEN NV
• Agilent Technologies Inc
• BGI Genomics
• PerkinElmer Inc
• Bio-Rad Laboratories Inc
• Danaher Corporation（Cepheid, IDT）
• Oxford Nanopore Technologies
• Pacific Biosciences
• Myriad Genetics Inc
• Guardant Health
• Eurofins Scientific
• GE HealthCare

第 10 章分析師建議

• 機會
• 一致的機會地圖

第 11 章參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Clinical Genomics Market is estimated to be valued at USD 12.5 Bn in 2025 and is expected to reach USD 26.3 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.2% from 2025 to 2032.

The Global Clinical Genomics Market represents a rapidly evolving sector within the healthcare industry, fundamentally transforming the landscape of personalized medicine and precision therapeutics. Clinical genomics encompasses the comprehensive analysis of an individual's genetic makeup to inform medical decision-making, disease diagnosis, treatment selection, and prognosis determination. This interdisciplinary field bridges the gap between genomic research and clinical practice, enabling healthcare providers to deliver tailored medical interventions based on patients' unique genetic profiles.

The market encompasses a broad spectrum of technologies, services, and applications including whole genome sequencing, targeted gene panels, pharmacogenomics testing, oncology genomics, and rare disease diagnostics. As healthcare systems worldwide increasingly adopt precision medicine approaches, clinical genomics has emerged as a cornerstone technology driving innovation in drug development, biomarker discovery, and therapeutic optimization. The integration of advanced sequencing technologies, artificial intelligence, and big data analytics has significantly enhanced the accessibility, accuracy, and cost-effectiveness of genomic testing, making it more viable for routine clinical implementation across diverse healthcare settings and patient populations globally.

Market Dynamics

The Global Clinical Genomics Market is propelled by several compelling drivers that continue to accelerate its growth trajectory. The increasing prevalence of genetic disorders, cancer, and rare diseases worldwide has created substantial demand for precise diagnostic and therapeutic solutions, positioning clinical genomics as an indispensable tool for healthcare providers. Technological advancements in next-generation sequencing (NGS), declining costs of genomic testing, and improved data interpretation capabilities have made genomic analysis more accessible and practical for widespread clinical adoption. Government initiatives and substantial investments in genomics research, including national genome projects and precision medicine programs, have provided significant momentum to market expansion.

The growing awareness among healthcare professionals and patients about the benefits of personalized medicine, coupled with increasing healthcare expenditure globally, further drives market growth. However, the market faces notable restraints including complex regulatory frameworks that vary across different regions, creating compliance challenges for market participants. High initial infrastructure costs, shortage of skilled genomics professionals, and concerns regarding data privacy and security pose significant barriers to market penetration, particularly in developing economies. Ethical considerations surrounding genetic testing and potential discrimination issues also limit market adoption. Nevertheless, substantial opportunities exist through expanding applications in pharmacogenomics, which enables optimized drug selection and dosing strategies, and the growing integration of artificial intelligence and machine learning technologies for enhanced data analysis and interpretation. Emerging markets present untapped potential for growth, while continuous innovation in point-of-care genomic testing and liquid biopsy technologies offers promising avenues for market expansion and improved patient outcomes.

Key Features of the Study

• This report provides an in-depth analysis of the global clinical genomics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global clinical genomics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Illumina Inc, Thermo Fisher Scientific Inc, F Hoffmann-La Roche Ltd, QIAGEN NV, Agilent Technologies Inc, BGI Genomics, PerkinElmer Inc, Bio-Rad Laboratories Inc, Danaher Corporation (Cepheid, IDT), Oxford Nanopore Technologies, Pacific Biosciences, Myriad Genetics Inc, Guardant Health, Eurofins Scientific, and GE HealthCare.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global clinical genomics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global clinical genomics market.

Market Segmentation

• Product and Service Insights (Revenue, USD Bn, 2020 - 2032)
  • Instruments or Systems
  • Sequencers
  • PCR Systems
  • Microarray Scanners
  • Automated Liquid Handlers
  • Other Genomic Analyzers
  • Consumables
  • Reagents and Kits
  • Sequencing Chips and Flow Cells
  • Sample Collection Kits
  • Others (Probes and Primers)
  • Software and Services
  • Data Analysis and Interpretation
  • Sequencing Services
  • Others (Clinical Laboratory Services, etc)
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Sanger Sequencing
  • Other Technologies (e.g., FISH, Karyotyping)
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Oncology
  • Cancer Diagnosis and Prognosis
  • Therapy Selection and Companion Diagnostics
  • Hereditary Cancer Risk Assessment
  • Minimal Residual Disease (MRD) Monitoring
  • Liquid Biopsy Analysis
  • Infectious Diseases
  • Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
  • Outbreak Surveillance and Strain Typing
  • Antimicrobial Resistance Testing
  • Genetic Disorders
  • Newborn Screening
  • Carrier Screening
  • Prenatal Diagnosis
  • Preimplantation Genetic Testing
  • Diagnosis of Rare and Inherited Diseases
  • Cardiovascular Diseases
  • Inherited Cardiomyopathies Testing
  • Arrhythmia Genetic Testing (e.g., Long QT Syndrome)
  • Aortopathies Genetic Testing (e.g., Marfan Syndrome)
  • Genetic Hypercholesterolemias Testing
  • Neurological Disorders
  • Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
  • Neuromuscular Disorder Testing (e.g., Duchenne Muscular Dystrophy)
  • Epilepsy Genetic Testing
  • Neurodevelopmental Disorder Testing
  • Other Applications (Pharmacogenomics, etc.)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Player Insights
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • F Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Agilent Technologies Inc
  • BGI Genomics
  • PerkinElmer Inc
  • Bio-Rad Laboratories Inc
  • Danaher Corporation (Cepheid, IDT)
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Myriad Genetics Inc
  • Guardant Health
  • Eurofins Scientific
  • GE HealthCare

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Clinical Genomics Market, By Product and Service
  • Global Clinical Genomics Market, By Technology
  • Global Clinical Genomics Market, By Application
  • Global Clinical Genomics Market, By End User
  • Global Clinical Genomics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Clinical Genomics Market, By Product and Service, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Instruments or Systems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Sequencers
  • PCR Systems
  • Microarray Scanners
  • Automated Liquid Handlers
  • Other Genomic Analyzers
• Consumables
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Reagents and Kits
  • Sequencing Chips and Flow Cells
  • Sample Collection Kits
  • Others (Probes and Primers)
• Software and Services
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Data Analysis and Interpretation
  • Sequencing Services
  • Others (Clinical Laboratory Services, etc.)

5. Global Clinical Genomics Market, By Technology, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Next-Generation Sequencing (NGS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Polymerase Chain Reaction (PCR)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Microarray
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Sanger Sequencing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Technologies (e.g., FISH, Karyotyping)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Clinical Genomics Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer Diagnosis and Prognosis
  • Therapy Selection and Companion Diagnostics
  • Hereditary Cancer Risk Assessment
  • Minimal Residual Disease (MRD) Monitoring
  • Liquid Biopsy Analysis
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
  • Outbreak Surveillance and Strain Typing
  • Antimicrobial Resistance Testing
• Genetic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Newborn Screening
  • Carrier Screening
  • Prenatal Diagnosis
  • Preimplantation Genetic Testing
  • Diagnosis of Rare and Inherited Diseases
• Cardiovascular Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inherited Cardiomyopathies Testing
  • Arrhythmia Genetic Testing (e.g., Long QT Syndrome)
  • Aortopathies Genetic Testing (e.g., Marfan Syndrome)
  • Genetic Hypercholesterolemia's Testing
• Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
  • Neuromuscular Disorder Testing (e.g., Duchenne Muscular Dystrophy)
  • Epilepsy Genetic Testing
  • Neurodevelopmental Disorder Testing
• Other Applications (Pharmacogenomics, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Clinical Genomics Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pharmaceutical and Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Academic and Research Institutes, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Clinical Genomics Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Illumina Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Thermo Fisher Scientific Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• QIAGEN NV
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Agilent Technologies Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BGI Genomics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• PerkinElmer Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bio-Rad Laboratories Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Danaher Corporation (Cepheid, IDT)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Oxford Nanopore Technologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pacific Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Myriad Genetics Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Guardant Health
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eurofins Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GE HealthCare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us